75672 Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices 

Drug Schedule 

Oxymorphone (9652) ................... II 

Racemethorphan (9732) .............. II 

Racemorphan (9733) ................... II 

The company plans to manufacture 

small quantities of the listed controlled 

substances in bulk for distribution to its 

customers for use as reference 

standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a), and 

determined that the registration of 

Chemtos, LLC, to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated 

Chemtos, LLC, to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above named company is 

granted registration as a bulk 

manufacturer of the basic classes of 

controlled substances listed. 

Dated: December 14, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–30781 Filed 12–20–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances, Notice of Registration, 

Halo Pharmaceutical, Inc. 

By Notice dated July 30, 2012, and 

published in the Federal Register on 

August 7, 2012, 77 FR 47114, Halo 

Pharmaceutical, Inc., 30 North Jefferson 

Road, Whippany, New Jersey 07981, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Hydromorphone (9150) ................ II 

Dihydromorphine is an intermediate 

in the manufacture of Hydromorphone 

and is not for commercial distribution. 

The company plans to manufacture 

Hydromorphone HCL for sale to other 

manufacturers, and for the manufacture 

of other controlled substance dosage 

units for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a), and 

determined that the registration of Halo 

Pharmaceutical, Inc., to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Halo Pharmaceutical, Inc., 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above named company is 

granted registration as a bulk 

manufacturer of the basic classes of 

controlled substances listed. 

Dated: December 14, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–30774 Filed 12–20–12; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL FOUNDATION ON THE 

ARTS AND THE HUMANITIES 

Arts Advisory Panel Meeting 

AGENCY: National Endowment for the 

Arts, National Foundation on the Arts 

and Humanities. 

ACTION: Notice of Meeting. 

SUMMARY: Pursuant to Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), as amended, notice is 

hereby given that seven meetings of the 

Arts Advisory Panel to the National 

Council on the Arts will be held at the 

Nancy Hanks Center, 1100 Pennsylvania 

Avenue NW., Washington, DC 20506 

(unless otherwise noted) as follows 

(ending times are approximate): 

International (application review): By 

teleoconference. This meeting will be 

closed. 

Dates: January 8, 2013; 1:00 p.m. to 

2:00 p.m. e.s.t. 

Folk & Traditional Arts (application 

review): In room 716. This meeting will 

be closed. 

Dates: January 11, 2013; 9:00 a.m. to 

5:30 p.m. e.s.t. 

State & Regional (review of state 

partnership agreements): In Room 716. 

This meeting will be open. 

Dates: January 16–17, 2013; From 9:00 

a.m. to 5:00 p.m. e.s.t. on January 16th 

and from 9:00 a.m. to 3:30 p.m. e.s.t. on 

January 17th. 

Music (review of nominations): 3 

Columbus Circle, 12th Floor, New York, 

NY 10019 and by teleconference. This 

meeting will be closed. 

Dates: January 15, 2013, from 9:00 

a.m. to 10:15 a.m. e.s.t. 

State & Regional (review of regional 

partnership agreements): By 

teleconference. This meeting will be 

open. 

Dates: January 30, 2013; From 3:00 

p.m. to 4:00 p.m. e.s.t. 

Folk & Traditional Arts (review of 

nominations): In room 716. This 

meeting will be closed. 

Dates: January 29–February 1, 2013; 

from 9:00 a.m. to 5:30 p.m. e.s.t. on 

January 29th–31st and from 9:00 a.m. to 

1:00 p.m. e.s.t. on February 1st. 

Research (application review): In 

Room 627. This meeting will be closed. 

Dates: January 29–30, 2013; From 9:00 

a.m. to 5:30 p.m. e.s.t. on January 29th 

and from 9:00 a.m. to 5:00 p.m. e.s.t. on 

January 30th. 

FOR FURTHER INFORMATION CONTACT: 

Further information with reference to 

these meetings can be obtained from Ms. 

Kathy Plowitz-Worden, Office of 

Guidelines & Panel Operations, National 

Endowment for the Arts, Washington, 

DC 20506; plowitzk@arts.gov or call 

202/682–5691. 

SUPPLEMENTARY INFORMATION: The 

closed portions of meetings are for the 

purpose of Panel review, discussion, 

evaluation, and recommendations on 

financial assistance under the National 

Foundation on the Arts and the 

Humanities Act of 1965, as amended, 

including information given in 

confidence to the agency. In accordance 

with the determination of the Chairman 

of February 15, 2012, these sessions will 

be closed to the public pursuant to 

subsection (c)(6) of section 552b of Title 

5, United States Code. 

Dated: December 18, 2012. 

Kathy Plowitz-Worden, 

Panel Coordinator, National Endowment for 

the Arts. 

[FR Doc. 2012–30759 Filed 12–20–12; 8:45 am] 

BILLING CODE 7537–01–P 

mstockstill on DSK4VPTVN1PROD with